peptides for alopecia areata FAQ

Combining topical GHK-Cu with self-administered subcutaneous TB-500 carries minimal drug interaction risk. The peptides operate through distinct pathways (copper-dependent enzyme activation vs immune cytokine modulation). However, subcutaneous TB-500 won't concentrate at follicle sites the way intralesional injection does, reducing efficacy. If attempting combination therapy, use topical GHK-Cu twice daily and reserve TB-500 for intralesional administration by a trained provider every two weeks. Self-injection into scalp tissue without sterile technique or proper needle gauge risks infection and scarring that worsens hair loss.

Eight weeks is insufficient for follicle cycling. Anagen phase reinitiation takes 12–16 weeks minimum. Continue for at least 16 weeks before concluding non-response. If no terminal hair regrowth appears by week 16, check the formulation: non-liposomal GHK-Cu fails to penetrate. Switch to a liposomal preparation or consider intralesional corticosteroids combined with peptides. Follicle miniaturization from prolonged immune attack may have progressed beyond peptide-responsive thresholds. Dermatoscopy showing complete follicle scarring indicates peptides won't reverse the damage.

Peptides alone cannot halt rapid autoimmune progression to totalis or universalis. If hair loss accelerates despite 12+ weeks of peptide use, systemic immunosuppression becomes necessary. JAK inhibitors like tofacitinib or baricitinib show 50–70% response rates in alopecia totalis per 2022 data from the National Alopecia Areata Foundation. Peptides can be continued as adjunct therapy once immune suppression stabilizes the condition, but they will not reverse totalis without concurrent immune modulation. Progression signals that the autoimmune cascade has overwhelmed local tissue-repair mechanisms.

Peptides show reduced efficacy in alopecia totalis (complete scalp hair loss) and alopecia universalis (total body hair loss) compared to patchy presentations. The immune dysregulation in totalis cases is systemic and sustained, meaning localized peptide intervention can't overcome the widespread T-cell activation. Published data on TB-500 and GHK-Cu comes primarily from patchy alopecia areata models where fewer than 50% of the scalp is involved. If you have totalis, JAK inhibitors like baricitinib or tofacitinib represent the current evidence-based first-line approach. These drugs systemically suppress JAK-STAT signaling that drives autoimmune hair loss. Peptides might serve as adjunctive therapy after JAK inhibitors establish immune suppression, but they aren't sufficient as monotherapy in severe cases.

Yes, peptides work through distinct mechanisms that don't overlap with corticosteroid anti-inflammatory pathways. Topical steroids like clobetasol reduce inflammation broadly but don't restore follicle vascularization or block NKG2D signaling. Combining GHK-Cu topical application with corticosteroid use is mechanistically sound. Apply the steroid in the morning and GHK-Cu in the evening to avoid interaction and allow each compound to exert its effect independently. TB-500 injections can run concurrently with steroid therapy without contraindication. One consideration: if you're using intralesional steroid injections (triamcinolone acetonide, the standard in-office treatment), coordinate injection sites with your dermatologist if also using TB-500 subcutaneously to avoid excessive dermal trauma in the same region.

Discard it immediately. Lyophilized peptides should dissolve into a clear, colorless solution when reconstituted with bacteriostatic water. Cloudiness indicates protein aggregation or bacterial contamination; discoloration (yellow, brown, or any tint) signals oxidation or degradation. Using compromised peptides risks injection site infection or complete loss of bioactivity. This is why reconstitution hygiene and cold-chain integrity matter. Peptides must be stored at -20°C before reconstitution, and the reconstituted solution must remain refrigerated at 2–8°C. Any supplier that ships lyophilized peptides without cold packs or temperature monitoring is failing basic stability requirements. Real Peptides ensures cold-chain shipping with thermal insulation and gel packs rated for 48-hour transit to maintain peptide integrity.